Phosphorylation of 20 kD myosin light chain (MLC) is a critical process in eliciting smooth muscle contraction. Excitatory receptor agonists increase the extent of MLC phosphorylation by both activating myosin light chain kinase (MLCK) and inhibiting myosin phosphatase (MP). Activation of MLCK is dependent on
INTRODUCTION
In smooth muscle including vascular smooth muscle, binding of excitatory receptor agonists to specific cell surface receptors, most of which belong to the seven membrane-spanning type of G protein-coupled receptors, leads to activation of phospholipase C and gating of Ca 2+ channels on the plasma membrane (1, 2) . The activation of phospholipase C produces the two second messengers, inositol-1,4,5-trisphosphate and 1,2-diacylglycerol. Inositol-1,4,5-trisphosphate induces Ca 2+ release from the intracellular Ca 2+ pool, which, together with stimulated Ca 2+ influx across the plasma membrane, causes an increase in the intracellular free Ca 2+ concentration ([Ca 2+ ] i ) (1) (2) (3) . An increase in [Ca 2+ ] i activates the Ca 2+ /calmodulindependent enzyme myosin light chain kinase (MLCK), which phosphorylates the 20 kD myosin light chain (MLC), leading to initiation of a contractile response (4) . An increase in the membrane content of 1,2-diacylglycerol leads to activation of protein kinase C, which activates a contractile mechanism © Bulgar ian Society for Cell Biology ISSN 1310-392X ] i ( Fig. 1 ) (1, 3) . Phosphorylation state of MLC is determined by the activities of the de-phosphorylating enzyme myosin phosphatase (MP) as well as by the phosphorylating enzyme MLCK (5, 6) . The smooth muscle-specific MP consists of three subunits: 38 kD catalytic subunit (PP1δ), 110 kD myosin targeting regulatory subunit (MYPT1/MBS) and 20 kD regulatory subunit (M20) (Fig. 2) (7) . Recent evidence indicates that the activity of MP is regulated by both constrictors and relaxants; constrictors inhibit MP activity whereas relaxants stimulate it (3, 5, 6) . Thus, excitatory receptor agonists such as noradrenaline and endothelin not only activate MLCK, but also inhibit MP, resulting in efficient phosphorylation of MLC. Conversely, relaxants such as the cyclic GMP-elevating natriuretic peptides inhibit MLCK and stimulate MP, resulting in an effective reduction of MLC phosphorylation (Fig. 1) . Accumulated data showed importance of the small G protein Rho as a switching 
MP Contraction
Calcium, Rho and myosin phosphatase in vascular smooth muscle molecule for regulating MP activity (3, 8) . In fact, excitatory receptor agonists induce activation of Rho in smooth muscle. In non-muscle cells, Rho regulates actin cytoskeletal assembly, controlling cell shape changes, migration and adhesion (9) . In many cell types, a particular family of the heterotrimeric G proteins named G 12/13 plays an important role in the regulation of Rho activity (10) . Unexpectedly, we recently discovered that membrane depolarization induced Rho activation in a Ca 2+ -dependent manner, as potently as excitatory receptor agonists (11) . This discovery provided considerable insight into understanding the regulatory mechanisms of MP and Ca
2+
-dependent contraction in smooth muscle. In this review, we will focus on the mechanisms of Rho regulation and Rhodependent MP inhibition in vascular smooth muscle, with particular emphasis on the novel Ca 2+ -dependent Rho and MP regulation mechanism.
MOLECULAR MECHANISMS OF RHO-MEDIATED CALCIUM SENSITIZATION
The development of membrane-permeabilized smooth muscle preparation contributed to our understanding of contractile mechanisms. In smooth muscle permeabilized with staphylococcal α-toxin and β-escin, excitatory receptor agonists including phenylephrine and thromboxane A2 potentiated contraction at a constant [Ca 2+ ] i , thus sensitizing contraction to Ca 2+ (12, 13) . This potentiation of contraction was accompanied by an increase in the extent of MLC phosphorylation. The potentiating actions of receptor agonists required GTP, and were mimicked and inhibited by the non-hydrolyzable guanine nucleotides, GTPγS and GDPβS, suggesting the involvement of a G protein in the potentiation of MLC phosphorylation and contraction. The first evidence for the role of Rho in smooth muscle contraction was provided by the observation that GTPγS-induced enhancement of Ca 2+ -induced contraction in permeabilized vascular smooth muscle was abolished by Staphylococcal exoenzyme epidermal cell differentiation inhibitor (EDIN) and Clostrium botulinum exotoxin C3 (14) , both of which specifically ADP-ribosylate and inactivate Rho. However, it was unknown how Rho was involved in smooth muscle contraction. We demonstrated for the first time that pretreatment of permeabilized vascular smooth muscle cells with C3 completely inhibited GTPγS enhancement of Ca 2+ -induced MLC phosphorylation (8), indicating that Rho was involved in Ca 2+ -induced MLC phosphorylation. Our observation implied the two possibilities, i.e. Rho might somehow potentiate MLCKcatalyzed phosphorylation of MLC and/or Rho might inhibit MP-catalyzed de-phosphorylation of MLC. We pursed both possibilities and discovered that Rho mediated inhibition of MP but not potentiation of MLCK activity, thus resulting in potentiation of MLC phosphorylation (8, 15) (Fig. 1) .
Active Rho directly binds to and regulates activities of several target proteins, which mediate many of Rho actions. These include the serine/threonine kinase Rho kinase/ROCK/ ROK, protein kinase N (PKN) and Citron kinase, and the non-kinase proteins mDia, Rhotekin and Rhophilin (9,16). Kimura et al (17) demonstrated that Rho kinase, but not PKN, phosphorylated the 110 kD MYPT1 subunit of purified myosin phosphatase holoenzyme in vitro. Importantly, Rho kinasecatalyzed phosphorylation of MYPT1 decreased phosphatase activity in vitro. Feng et al (18) identified Thr 695 of MYPT1 (numbering of chicken M133 isoform) as an inhibitory phosphorylation site. Rho kinase also phosphorylates MYPT1 at Thr 850 phosphorylation, which is shown to inhibit the binding of MP to myosin (19) . Recent investigations (20, 21) demonstrated that receptor agonists increased the extent of MYPT1 phosphorylation more definitely at Thr 850 rather than at Thr 695 . We showed that the two structurally different Rho kinase inhibitors Y27632 and HA1077 abolished GTPγS-induced potentiation of Ca 2+ -induced MLC phosphorylation in permeabilized smooth muscle cells, but not MLC phosphorylation induced by Ca 2+ alone (15) . Moreover, we found that HA1077 abolished GTPγS-induced inhibition of MP activity by the immunoprecipitation-phosphatase assay in vivo. The prevention of GTPγS-induced MP suppression by the Rho kinase inhibitor was accompanied by inhibition of GTPγS-induced MYPT1 phosphorylation although the phosphorylation site of MYPT1 was not determined (15) . Recent investigatons (20, 21) demonstrated that the Rho kinase inhibitors suppressed MYPT1 phosphorylation at Thr 850 in vivo. Altogether, these observations indicate that Rho kinase mediates Rho-dependent MP inhibition through mechanisms involving MYPT1 phosphorylation in smooth muscle (Fig.  2) .
The inhibitory phosphorylation site of MYPT1 (Thr 695 ), was also shown to be phosphorylated in vitro by other kinases including ZIP/MYPT1-kinase (22) and integrin-linked kinase (ILK) (23) . However, it is not known whether these kinases are involved in regulation of smooth muscle myosin phosphatase activity in vivo. It is either unknown whether Rho is somehow linked to regulation of activities of these kinases.
Protein kinase C-potentiated phosphatase inhibitor of 17 kD (CPI-17) is an endogenous smooth muscle-specific inhibitor protein for myosin phosphatase (24) . In particular, CPI-17 is abundantly expressed in vascular smooth muscle. The phosphatase-inhibitory activity of CPI-17 is very low in its non- (25) . Rho kinase inhibitors also reduced agonist-induced phosphporylation of CPI-17 (26) . These observations suggest that CPI-17 becomes active as a MP inhibitor through its phosphorylation by protein kinases including Rho kinase and protein kinase C, participating in MP inhibition (Fig. 2) .
REGULATION OF RHO BY EXCITATORY AGONISTS
Despite accumulation of the observations showing the importance of the Rho-signaling pathway in the regulation of smooth muscle contraction, no direct effect of excitatory agonists on Rho activity in smooth muscle was yet demonstrated. Rho cycles between a GDP-bound inactive state and a GTP-bound active state, like Ras (9). We recently developed a new biochemical assay which employs a recombinant RhoA-binding protein, Rhotekin, for determining amounts of active GTP-bound form of RhoA (GTP-Rho) in smooth muscle tissues (27) . In rabbit aortic smooth muscle, the thromboxane A 2 mimetic U46619, which induced a sustained contractile response, caused a sustained rise in the amount of GTP-Rho in a dose-dependent manner with an EC 50 value Calcium, Rho and myosin phosphatase in vascular smooth muscle similar to that for the contractile response. U46619-induced Rho activation was thromboxane A 2 receptor-mediated and reversible. Other agonists including noradrenaline, serotonin, histamine and endothelin-1 also stimulated Rho, albeit to a lesser extent than U46619. In contrast, angiotensin II and phorbol 12,13-dibutyrate failed to increase GTP-Rho. The tyrosine kinase inhibitor genistein substantially inhibited Rho activation by these agonists, except for endothelin-1. Thus, the magnitude and mode of agonist-induced Rho activation does not appear to be uniform among agonists.
The cycling of Rho between the GTP-bound active and GDP-bound inactive states is under the tight regulation by the two major groups of proteins, guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs) (9, 28) . Previous studies, largely on non-muscle cells, demonstrated that stimulation with G protein-coupled receptor agonists including lysophosphatidic acid, endothelin-1 and thrombin induced Rho activation, which was mediated through the receptor coupling to the G 12/13 family of the heterotrimeric G proteins (29) . Indeed, direct physical and functional interaction of Gα 12/13 with a group of structurally related GEFs that act on Rho (RhoGEFs) was demonstrated (30) . More recent studies (30, 31) showed that G q also had the ability to mediate stimulation of Rho, but the signaling pathway that mediates G q -mediated Rho stimulation is still incompletely understood although a Gα q -RhoGEFs interaction was observed. In cultured vascular smooth muscle cells, the expression of activated forms of Gα 12 and Gα 13 but not Gα q was shown to induce a contraction that was inhibited by C3 toxin and a Rho kinase inhibitor, whereas the expression of dominant negative forms of Gα 12 and Gα 13 inhibited receptor agonist-induced, C3 toxin-and Rho kinase inhibitor-sensitive contraction (10) . Thus, these observations indicated that G 12/13 mediates Rhoand Rho kinase-dependent contraction in receptor agoniststimulated cultured vascular smooth muscle cells. However, our observations described above suggest that more than a single mechanism for activating Rho might be operating in smooth muscle.
CALCIUM-DEPENDENT RHO ACTIVATION AND MYOSIN PHOSPHATASE INHIBITION
We recently found a novel, Ca 2+ -dependent mechanism for Rho activation in vascular smooth muscle. High KCl-induced membrane depolarization caused sustained increases in GTP-Rho with stimulation of MYPT1 phosphorylation in rabbit aortic smooth muscle, as well as the receptor agonist noradrenaline (11 ] i (32) . This suggests the possibility that receptor agonist-induced Rho activation might also be dependent on Ca 2+ although G protein-coupled receptors were shown to mediate Rho activation via G 12/13 in vascular smooth muscle cells (10) and non-muscle cells (29) . Excitatory receptor agonists mobilize Ca 2+ from both the intracellular and extracellular pools. The combination of extracellular Ca 2+ removal and depletion of the intracellular Ca 2+ store by using caffeine pretreatment almost completely abolished agonist-induced Ca 2+ mobilization in smooth muscle (11) . Rho stimulation and contraction induced by noradrenaline and thromboxane A2 analogue U46619 was inhibited by this procedure, indicating that receptor agonistinduced Rho activation was Ca 2+ -dependent. Intriguingly, noradrenaline-and U46619-induced Rho activation was Ca 2+ -dependent to a varying degree: the Ca 2+ -depletion procedure totally abolished noradrenaline-induced Rho activation whereas it only partially inhibited U46619-induced Rho activation. Thus, U46619-induced Rho activation was less dependent on Ca
2+
. The results, together with the previous observation that U46619 is less effective in mobilizing Ca 2+ (33) , suggest that U46619-induced Rho activation is more strongly dependent on G 12/13 than on noradrenaline. Most likely, the Ca 2+ -dependent mechanism for activating Rho operates in cooperation with a G 12/13 -mediated mechanism. Because G q mediates Ca 2+ -mobilization via activation of phospholipase C, multitudes of heterotrimeric G protein-mediated signaling pathways likely regulate Rho activity in excitatory receptor agonist-stimulated vascular smooth muscle (Fig. 3) .
It was unknown how Ca 2+ is involved in Rho regulation in smooth muscle. During our investigation into the molecular mechanisms of Ca 2+ -dependent Rho activation, we found that phosphoinositide 3-kinase (PI3K) inhibitors suppressed membrane depolarization-induced Rho activation and contraction with suppression of MYPT1 and MLC Takuwa, Yoshioka, Takuwa, Wang, Azam, and Sugimoto phosphorylation (34) . The structurally different two PI3K inhibitors wortmannin and LY294002 exerted similar extents of maximal inhibition for contraction and Rho activation, suggesting that inhibition of a PI3K is a mechanism for Rho suppression by the inhibitors. Notably, the EC 50 values of these inhibitors for suppression of contraction and Rho were higher than those previously reported for inhibition of PI3K-mediated effects including Akt stimulation and cell survival (35) . PI3Ks are divided into three main classes based on their structure and substrate preference (35, 36) . Class I enzymes are heterodimers of the catalytic subunits including p110α, p110β, p110γ and p110δ and the regulatory subunits including p85 and p101. Class I enzymes are rapidly activated by a variety of receptor tyrosine kinases and/or G protein-coupled receptors and exert such diverse biological activities as cell proliferation, survival, motility and control of carbohydrate metabolism. Previous studies identified Akt as an important downstream effector of class I PI3Ks (36) . Class II enzymes include PI3K-C2α, -β, and -γ isoforms. It is poorly understood how their activities are regulated and what physiological functions they serve. Class III enzyme, a homologue of yeast Vps34p, plays an important role in vesicular trafficking. LY294002 and wortmannin inhibit these PI3K enzymes with similar potencies, except PI3K-C2α that is at least one order less sensitive to either of PI3K inhibitors (35, 37) . In vascular smooth muscle, at least 4 PI3K isoforms, class I p110α and p110β, class II PI3K-C2α, and PI3K-C2β, were detected. We immunoprecipitated each of p110α, p110β and PI3K-C2α from vascular smooth muscle, and determined their sensitivities to wortmannin. We found that PI3K-C2α was less sensitive to wortmannin than p110α and p110β. This observation suggested that PI3K-C2α might mediate Rho activation and contraction. To directly test this possibility, we examined the effect of small interfering RNA (siRNA)-mediated PI3K-C2α down-regulation on contraction 
MLC-
Calcium, Rho and myosin phosphatase in vascular smooth muscle in vascular smooth muscle cells. The vascular smooth muscle cells, which are enzymatically dispersed from aortic media and cultured in the serum-free chemically defined medium, maintain contractile responses to various vasoactive substances including noradrenaline (38) . Down-regulation of PI3K-C2α by approximately 70% inhibited noradrenaline-induced contraction and MYPT1 phosphorylation (34) . In contrast, down-regulation of p110α did not inhibit noradrenalineinduced contraction or MYPT1 phosphorylation. These observations indicate that PI3K-C2α is involved in Ca 2+ -dependent Rho activation and resultant negative regulation of MP, thus contributing to MLC phosphorylation and contraction (Fig. 3) . This is the first demonstration of the novel role of class II PI3K in the regulation of vascular system
The discovery of the Ca 2+ -dependent Rho activation suggests that membrane depolarization induces Rho-dependent MP inhibition in vivo. Smooth muscle is depolarized by excitatory receptor agonists and mechanical strains (39) . Vascular smooth muscle is constantly exposed to stretch derived from the intravascular pressure. Stretch of vascular smooth muscle induces gating of cation channels, resulting in membrane depolarization and stimulation of Ca 2+ influx through voltage-dependent Ca 2+ channels. Likely, the resultant increase of [Ca 2+ ] i activates not only MLCK but also Rho, the latter of which leads to MP inhibition and potentiation of MLC phosphorylation and thereby contraction. We observed that intravenous wortmannin infusion induced a decrease in the arterial blood pressure with inhibition of arterial PI3K-C2α activity, Rho activity and MYPT1 phosphorylation (34) , suggesting that PI3K-C2α-dependent Rho and MP regulation is operating in the blood vessel in vivo. Thus, Ca 2+ -dependent Rho activation likely contributes to vascular tone regulation.
CONCLUSION
Since we first reported in 1995 that agonist-induced Ca 2+ sensitization of smooth muscle MLC phosphorylation and contraction involves Rho-dependent inhibition of myosin phosphatase (8) , great progress has been made in understanding the mechanisms of Rho-dependent Ca 2+ sensitization. Excitatory receptor agonists, most of which act on heptahelical G protein-coupled receptors, stimulate Rho through multitudes of mechanisms involving G 12/13 and G q -Ca 2+ (11) . The Ca 2+ -dependent mechanism has thus far been unrecognized in nonmuscle cells and may be unique to smooth muscle. Activation of Rho phosphorylates the regulatory subunit MYPT1 of MP via Rho kinase (6) . Rho kinase may also phosphporylate to activate the MP inhibitor phosphoprotein CPI-17 (5) . Recent studies demonstrated the possibilities that several other serine/ threonine kinases may also be involved in phosphorylation of both MYPT1 and CPI-17, and thus in the regulation of MP activity (5, 6) . Consistent with the roles for Rho kinase in agonist-induced contraction, Rho kinase inhibitors reduce agonist-induced contraction. These observations support the model for the signaling of agonist-induced contraction, in which activation of receptors by excitatory agonists triggers Ca 2+ mobilization and consequent activation of MLCK via G q , as well as Rho-Rho kinase-dependent inhibition of MP via G 12/13 and G q . The activation of MLCK and inhibition of MP operate in concert to result in efficient phosphorylation of MLC and contraction (Fig. 3) . Protein kinase C was recently shown to be involved in inhibition of MP through phosphorylation of CPI-17. However, a number of previous studies also suggested that protein kinase C contributes to contraction in a manner independent of MLC phosphorylation (1, 3) . Thus, the protein kinase C branch of the G q -signaling may regulate both MLC phosphorylation-dependent and -independent mechanisms of contraction.
